BR0311708A - Comprimidos que se desintegram oralmente e processo de obtenção dos mesmos - Google Patents

Comprimidos que se desintegram oralmente e processo de obtenção dos mesmos

Info

Publication number
BR0311708A
BR0311708A BR0311708-1A BR0311708A BR0311708A BR 0311708 A BR0311708 A BR 0311708A BR 0311708 A BR0311708 A BR 0311708A BR 0311708 A BR0311708 A BR 0311708A
Authority
BR
Brazil
Prior art keywords
weight
tablets
particle size
active ingredient
microcrystalline cellulose
Prior art date
Application number
BR0311708-1A
Other languages
English (en)
Inventor
Javier Segado Ferran
Original Assignee
Vita Cientifica S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29724735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0311708(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vita Cientifica S L filed Critical Vita Cientifica S L
Publication of BR0311708A publication Critical patent/BR0311708A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPRIMIDOS QUE SE DESINTEGRAM ORALMENTE E PROCESSO DE OBTENçãO DOS MESMOS". Os comprimidos compreendem: pelo menos 59,5 % de manitol seco em atomização; ingrediente ativo abaixo ou igual a 10 %, em que pelo menos 90 % em peso do ingrediente ativo têm um tamanho de partícula abaixo de que 100 <109>m; celulose microcristalina 10 - 18 %, com um tamanho médio de partícula de 50 <109>m e em que pelo menos 99 % em peso de celulose microcristalina têm um tamanho de partícula abaixo de 250 <109>m; croscarmelose de sódio 1 - 4 % e um agente lubrificante 0,5 - 2 %; em que, a não ser se for especificado de outra maneira, as percentagens estão expressas em peso do peso total do comprimido. E também um processo que compreende: peneiração e misturação de componentes exceto para o agente lubrificante; misturação de todos os componentes e compressão direta da mistura final. Os comprimidos da invenção fornecem menores tempos de desintegração assim como boa percepção sobre a língua após a desintegração e superam o problema de resistência mecânica insuficiente para operações de embalagem e de transporte.
BR0311708-1A 2002-06-10 2003-06-04 Comprimidos que se desintegram oralmente e processo de obtenção dos mesmos BR0311708A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200201440A ES2199061B1 (es) 2002-06-10 2002-06-10 Comprimidos bucodispersables y procedimiento para su obtencion.
PCT/IB2003/002446 WO2003103629A1 (en) 2002-06-10 2003-06-04 Orally disintegrating tablets and process for obtaining them.

Publications (1)

Publication Number Publication Date
BR0311708A true BR0311708A (pt) 2005-03-15

Family

ID=29724735

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311708-1A BR0311708A (pt) 2002-06-10 2003-06-04 Comprimidos que se desintegram oralmente e processo de obtenção dos mesmos

Country Status (33)

Country Link
US (1) US20060165781A1 (pt)
EP (1) EP1534237B1 (pt)
JP (1) JP2005533045A (pt)
KR (1) KR100826819B1 (pt)
CN (1) CN100428926C (pt)
AR (1) AR040183A1 (pt)
AT (1) ATE422154T1 (pt)
AU (1) AU2003232415B2 (pt)
BR (1) BR0311708A (pt)
CA (1) CA2487834C (pt)
CY (1) CY1108961T1 (pt)
DE (1) DE60326074D1 (pt)
DK (1) DK1534237T3 (pt)
EG (1) EG25919A (pt)
ES (2) ES2199061B1 (pt)
HK (1) HK1076252A1 (pt)
HR (1) HRP20041158B1 (pt)
IL (1) IL165523A (pt)
JO (1) JO2560B1 (pt)
MA (1) MA27309A1 (pt)
MX (1) MXPA04012464A (pt)
MY (1) MY139585A (pt)
NO (1) NO334159B1 (pt)
NZ (1) NZ536966A (pt)
PE (1) PE20040069A1 (pt)
PL (1) PL207009B1 (pt)
PT (1) PT1534237E (pt)
RU (1) RU2321389C2 (pt)
SA (1) SA03240275B1 (pt)
SI (1) SI1534237T1 (pt)
TW (1) TWI288002B (pt)
WO (1) WO2003103629A1 (pt)
ZA (1) ZA200409894B (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7815937B2 (en) * 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
WO2000024380A1 (en) * 1998-10-27 2000-05-04 Fuisz Technologies Ltd. Microparticles containing peg and/or peg glyceryl esters
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
CA2540040C (en) * 2003-10-07 2012-09-11 Andrx Pharmaceuticals Llc Rapidly disintegrating formulation
ES2238001B1 (es) 2004-01-21 2006-11-01 Vita Cientifica, S.L. Nuevas formas polimorficas de ondansetron, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso como aantiemeticos.
JP2005306770A (ja) * 2004-04-21 2005-11-04 Toa Eiyo Ltd 口腔内速崩壊型製剤及びその製造方法
IS7290A (is) * 2004-05-28 2005-11-29 Actavis Group Lyfjasamsetningar sem innihalda risperidone
DE102004034043A1 (de) * 2004-07-13 2006-02-09 Krka Tovarna Zdravil, D.D. Feste pharmazeutische Zusammensetzung, die Mirtazapin enthält
GB0423800D0 (en) 2004-10-27 2004-12-01 Orexo Ab New pharmaceutical formulations
WO2006087629A2 (en) * 2005-02-21 2006-08-24 Aurobindo Pharma Limited Rapidly disintegrating composition of olanzapine
TWI383809B (zh) * 2005-06-29 2013-02-01 Otsuka Pharma Co Ltd 含有西洛他唑（ｃｉｌｏｓｔａｚｏｌ）之口腔崩解粉末
US20070092586A1 (en) * 2005-10-26 2007-04-26 Alamo Pharmaceuticals Compositions and methods for the administration psychotropic drugs which modulate body weight
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
CN100360128C (zh) * 2005-12-23 2008-01-09 北京科信必成医药科技发展有限公司 石杉碱甲口腔崩解片及其制备方法
CN100457100C (zh) * 2005-12-23 2009-02-04 北京科信必成医药科技发展有限公司 甲氧氯普胺口腔崩解片及其生产方法
EP1852108A1 (en) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US20080254118A1 (en) * 2007-04-11 2008-10-16 Hans-Werner Wernersbach Process for preparing pramipexole dihydrochloride tablets
WO2008057267A2 (en) * 2006-10-27 2008-05-15 Fmc Corporation Co-processed microcrystalline cellulose and sugar alcohol as an excipient for tablet formulations
US20080254117A1 (en) * 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
TWI547282B (zh) * 2007-07-02 2016-09-01 愛戴爾製藥股份有限公司 樂命達之口服分解錠劑組合物
EP2572705B1 (en) 2007-10-01 2017-09-13 Laboratorios Lesvi, S.L. Orodispersible tablets
SI3354276T1 (sl) 2007-11-13 2020-09-30 Meritage Pharma, Inc. Sestavki za zdravljenje gastrointestinalnega vnetja
AU2008321418A1 (en) * 2007-11-14 2009-05-22 Jose Becera New extracts of deschampsia antarctica desv. with antineoplastic activity
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
CN102088959B (zh) * 2008-06-20 2016-05-25 默克专利股份有限公司 可直接压缩的且快速崩解的片剂基质
FR2933299B1 (fr) 2008-07-04 2012-02-03 Roquette Freres Mannitol orodispersible
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
KR101033975B1 (ko) * 2008-10-10 2011-05-11 이희엽 직접압축법을 이용한 발사르탄 함유 고형 경구 제형의 제조방법 및 이에 따라 제조된 고형 경구 제형
EP2198857A1 (en) 2008-12-19 2010-06-23 Ratiopharm GmbH Oral dispersible tablet
DE102009016584A1 (de) * 2009-04-06 2010-10-07 Ratiopharm Gmbh Schmelztablette, enthaltend ein Sildenafil-Salz
CN101874790B (zh) * 2009-04-29 2012-06-06 齐鲁制药有限公司 雷沙吉兰或者其药用盐口腔崩解片及其制备方法
CN101904824B (zh) * 2009-06-04 2012-07-18 齐鲁制药有限公司 奥氮平口崩片制剂及其制备方法
US20110097401A1 (en) 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US20110105441A1 (en) * 2009-10-30 2011-05-05 Fmc Corporation Stable Orally Disintegrating Tablets Having Low Superdisintegrant
MX364651B (es) 2009-11-27 2019-05-03 Boehringer Ingelheim Int Gmbh Star Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmacéuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabéticos tipificados genéticamente.
EP2515879A4 (en) * 2009-12-22 2014-04-02 Fmc Corp Inc FINE PARTICLE CROSCARMELLOSIS AND USES THEREOF
WO2011138797A2 (en) 2010-05-04 2011-11-10 Cadila Healthcare Limited Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
EP2566469B1 (en) 2010-05-05 2022-12-21 Boehringer Ingelheim International GmbH Combination therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6084826B2 (ja) * 2012-11-27 2017-02-22 古河産機システムズ株式会社 造粒物検査装置および造粒物の検査方法
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
WO2017038455A1 (ja) * 2015-09-04 2017-03-09 株式会社ダイセル 超速崩壊錠剤及びその製造方法
CN107789328B (zh) * 2016-09-07 2021-02-26 成都康弘药业集团股份有限公司 一种含有盐酸多奈哌齐的口崩片及其制备方法
KR102290312B1 (ko) 2017-04-10 2021-08-17 주식회사 엘지생활건강 정제 조성물 및 이의 제조방법
JP7203726B2 (ja) * 2017-06-27 2023-01-13 第一三共株式会社 錠剤
AU2020407163A1 (en) * 2019-12-16 2022-07-21 Minute Molecular Diagnostics, Inc. Lyophilized reagents
CN113730365A (zh) * 2021-08-10 2021-12-03 杭州新诺华医药有限公司 一种奥氮平口腔崩解片及其制备方法
CN114224855B (zh) * 2021-12-01 2023-11-28 北京悦康科创医药科技股份有限公司 一种甲磺酸多沙唑嗪口含片及其制备方法
CN116251067B (zh) * 2023-04-23 2024-06-07 淄博市中心医院 一种氟康唑片、制备方法及用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0272265B1 (de) * 1985-09-25 1991-05-22 Gergely, Gerhard, Dr. Zerfallstablette und verfahren zu ihrer herstellung
IT1238072B (it) * 1990-01-19 1993-07-03 Sclavo Spa Composizioni farmaceutiche e forme di dosaggio per la somministrazione orale di calcitonina
FR2710637B1 (fr) * 1993-09-28 1995-12-08 Roquette Freres Mannitol pulvérulent de friabilité modérée et son procédé de préparation.
FR2722408B1 (fr) * 1994-07-15 1996-10-04 Vacher Dominique Nouveau procede de realisation de formes pharmaceutiques seches a delitement quasiment instantane etles formes pharmaceutiques ainsi realisees
US5686107A (en) * 1995-01-30 1997-11-11 Fmc Corporation Chewable pharmaceutical tablets
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
JPH10298062A (ja) * 1997-04-24 1998-11-10 Pfizer Pharmaceut Co Ltd 口腔内速溶型錠剤
US5904937A (en) * 1997-10-03 1999-05-18 Fmc Corporation Taste masked pharmaceutical compositions
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
US6740339B1 (en) * 1999-06-18 2004-05-25 Takeda Chemical Industries, Ltd. Quickly disintegrating solid preparations
JP2001058944A (ja) * 1999-06-18 2001-03-06 Takeda Chem Ind Ltd 速崩壊性固形製剤
CA2380449A1 (en) * 1999-08-17 2001-02-22 Novartis Consumer Health S.A. Rapidly dissolving dosage form and process for making same
CA2342121C (fr) * 2000-03-29 2010-05-25 Roquette Freres Mannitol pulverulent et son procede de preparation

Also Published As

Publication number Publication date
HRP20041158A2 (en) 2005-04-30
ZA200409894B (en) 2006-05-31
AR040183A1 (es) 2005-03-16
US20060165781A1 (en) 2006-07-27
SA03240275B1 (ar) 2008-11-19
SI1534237T1 (sl) 2009-06-30
MXPA04012464A (es) 2005-06-08
DK1534237T3 (da) 2009-05-04
AU2003232415A1 (en) 2003-12-22
KR20050062467A (ko) 2005-06-23
EP1534237A1 (en) 2005-06-01
AU2003232415B2 (en) 2008-05-15
RU2004135377A (ru) 2005-09-10
ES2199061A1 (es) 2004-02-01
PE20040069A1 (es) 2004-03-25
JP2005533045A (ja) 2005-11-04
CN1658838A (zh) 2005-08-24
CN100428926C (zh) 2008-10-29
IL165523A0 (en) 2006-01-15
DE60326074D1 (de) 2009-03-19
EG25919A (en) 2012-10-15
CA2487834A1 (en) 2003-12-18
HK1076252A1 (en) 2006-01-13
PT1534237E (pt) 2009-05-05
CY1108961T1 (el) 2014-07-02
MA27309A1 (fr) 2005-05-02
NO334159B1 (no) 2013-12-23
ES2199061B1 (es) 2005-02-16
ATE422154T1 (de) 2009-02-15
RU2321389C2 (ru) 2008-04-10
CA2487834C (en) 2009-07-14
TW200403080A (en) 2004-03-01
NZ536966A (en) 2006-08-31
NO20045577L (no) 2004-12-21
IL165523A (en) 2011-07-31
ES2320753T3 (es) 2009-05-28
PL374197A1 (en) 2005-10-03
PL207009B1 (pl) 2010-10-29
MY139585A (en) 2009-10-30
EP1534237B1 (en) 2009-02-04
HRP20041158B1 (en) 2012-11-30
JO2560B1 (en) 2010-09-05
KR100826819B1 (ko) 2008-05-02
TWI288002B (en) 2007-10-11
WO2003103629A1 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
BR0311708A (pt) Comprimidos que se desintegram oralmente e processo de obtenção dos mesmos
AU2019272064A1 (en) High dosage strength tablets of rucaparib
BR9811987A (pt) Comprimidos de metil celulose de rápida desintegração
DE69730834T2 (de) Verfahren zur herstellung von festen oralen dosierungsformen von valsartan
BR9811980A (pt) Comprimidos de metilcelulose de rápida desintegração
BR0116556A (pt) Composição farmacêutica e seu uso, processo para tratamento ou prevenção de angina ou hipertensão ou falha cardìaca, processo para fazer a composição, processo e comprimido
NZ611467A (en) Rapidly dispersing granules, orally disintegrating tablets and methods
HRP20100674T1 (hr) Farmaceutski pripravak koji sadrzi omega-karboksiaril supstituirani difenil ureu za lijecenje raka
HK1147202A1 (en) Orally disintegrated dosage form
BR0016482A (pt) Método para melhorar a compressibilidade de um superdesintegrante, obter um complexo de preparado de droga superdesintegrante altamente compatìvel , superdesintegrante aumentado e sua forma de dosagem sólida
BRPI0513417A (pt) composição farmacêutica estável, usos de um poliol, e de uma composição, processo para preparar uma composição farmacêutica, e, método para tratar uma condição responsiva à administração de uma anti-histamina
BR0307666A (pt) Composição farmacêutica compreendendo n-[(1-n-butil-4-piperidinil)metil]-3,4-diidro-2h[1-3]oxazi no(3,2-a) indol-10-carboxamida ou sal e processo para esta compreendendo granulação seca
BRPI0412391A (pt) formulação farmacêutica compreendendo levotiroxina sódica
JP6009967B2 (ja) 固形製剤
BRPI0503775A (pt) composição que compreende um amido parcialmente pré-gelatinizado e método de preparar o mesmo
CN101528201B (zh) 作为片剂配料赋形剂的共处理的微晶纤维素和糖醇
WO2007052307A3 (en) Stable solid oral dosage forms of valsartan
CN101822684A (zh) 用于防治骨关节痛的复方组合制剂及其制备方法
IL200447A0 (en) Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
AR049117A1 (es) Granulos con alto contenido de ibuprofeno y su preparacion y su uso en formas de dosificacion farmaceutica
BR112012030652A2 (pt) comprimidos que podem ser dispersos oralmente de eritritol e isomalte
UY24437A1 (es) Procedimiento para preparar productos farmaceuticos
Popa et al. Study on the influence of Gelucire sort on the release of acetaminophen from orally disintegrating tablets
PL223223B1 (pl) Sposób wytwarzania tabletki o zwiększonej dostępności farmaceutycznej worykonazolu
UY26706A1 (es) Procedimiento para preparar composiciones farmacéuticas en comprimidos de desintegración rápida sustancialmente exentos de cristales del principio farmacológicamente activo provenientes de la modificación de la estructura cristalina de dicho agente d

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI.A61K 47/26, A61K 47/36, A61K 47/38, A61K 9/00, A61K 9/20

Ipc: A61K 47/26 (2011.01), A61K 47/36 (2011.01), A61K 4

B25D Requested change of name of applicant approved

Owner name: PROCTER AND GAMBLE PHARMACEUTICALS IBERIA, S.L. (E

Free format text: NOME ALTERADO DE: VITA CIENTIFICA, S.L.

B25G Requested change of headquarter approved

Owner name: PROCTER AND GAMBLE PHARMACEUTICALS IBERIA, S.L. (E

Free format text: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 020100112989/RJ DE 03/12/2010.

B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: PROCTER AND GAMBLE PHARMACEUTICALS IBERIA, S.L. (E

Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO NO 020110112133/RJ DE 03/11/2011, E NECESSARIO COMPLEMENTAR A GUIA REFERENTE A ESTE SERVICO.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: WARNER CHILCOTT IBERIA, S.L. (ES)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25B Requested transfer of rights rejected

Owner name: WARNER CHILCOTT IBERIA, S.L. (ES)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]